These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31461080)

  • 1. Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system.
    Fohner AE; Ranatunga DK; Thai KK; Lawson BL; Risch N; Oni-Orisan A; Jelalian AT; Rettie AE; Liu VX; Schaefer CA
    Pharmacogenet Genomics; 2019 Oct; 29(8):192-199. PubMed ID: 31461080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions.
    Fohner AE; Rettie AE; Thai KK; Ranatunga DK; Lawson BL; Liu VX; Schaefer CA
    Clin Transl Sci; 2020 Sep; 13(5):1004-1009. PubMed ID: 32216088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.
    Ortega-Vázquez A; Dorado P; Fricke-Galindo I; Jung-Cook H; Monroy-Jaramillo N; Martínez-Juárez IE; Familiar-López I; Peñas-Lledó E; LLerena A; López-López M
    Pharmacogenomics J; 2016 Jun; 16(3):286-92. PubMed ID: 26122019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
    Franco V; Perucca E
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1269-79. PubMed ID: 26037375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.
    Chaudhary N; Kabra M; Gulati S; Gupta YK; Pandey RM; Bhatia BD
    BMC Pediatr; 2016 May; 16():66. PubMed ID: 27179628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of genetic polymorphism in CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance.
    Kousar S; Wafai ZA; Wani MA; Jan TR; Andrabi KI
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):504-16. PubMed ID: 25943175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
    Chang WC; Hung SI; Carleton BC; Chung WH
    Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):723-734. PubMed ID: 32510242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of CYP2C9 polymorphism and phenytoin co-administration on acenocoumarol dose in patients with cerebral venous thrombosis.
    De T; Christopher R; Nagaraja D
    Thromb Res; 2014 May; 133(5):729-35. PubMed ID: 24530212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes.
    Yamamoto Y; Takahashi Y; Imai K; Miyakawa K; Ikeda H; Ueda Y; Yamaguchi T; Nasu H; Ohtani H; Shigematsu H; Kagawa Y; Inoue Y
    Ther Drug Monit; 2015 Apr; 37(2):229-35. PubMed ID: 25162219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.
    Karnes JH; Rettie AE; Somogyi AA; Huddart R; Fohner AE; Formea CM; Ta Michael Lee M; Llerena A; Whirl-Carrillo M; Klein TE; Phillips EJ; Mintzer S; Gaedigk A; Caudle KE; Callaghan JT
    Clin Pharmacol Ther; 2021 Feb; 109(2):302-309. PubMed ID: 32779747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
    van der Weide J; Steijns LS; van Weelden MJ; de Haan K
    Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.
    Caudle KE; Rettie AE; Whirl-Carrillo M; Smith LH; Mintzer S; Lee MT; Klein TE; Callaghan JT;
    Clin Pharmacol Ther; 2014 Nov; 96(5):542-8. PubMed ID: 25099164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-B*51:01 and CYP2C9*3 Are Risk Factors for Phenytoin-Induced Eruption in the Japanese Population: Analysis of Data From the Biobank Japan Project.
    Hikino K; Ozeki T; Koido M; Terao C; Kamatani Y; Mizukawa Y; Shiohara T; Tohyama M; Azukizawa H; Aihara M; Nihara H; Morita E; Murakami Y; Kubo M; Mushiroda T
    Clin Pharmacol Ther; 2020 May; 107(5):1170-1178. PubMed ID: 31646624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
    Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B
    Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.
    Kerb R; Aynacioglu AS; Brockmöller J; Schlagenhaufer R; Bauer S; Szekeres T; Hamwi A; Fritzer-Szekeres M; Baumgartner C; Ongen HZ; Güzelbey P; Roots I; Brinkmann U
    Pharmacogenomics J; 2001; 1(3):204-10. PubMed ID: 11908757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.
    Lin CJ; Yen MF; Hu OY; Lin MS; Hsiong CH; Hung CC; Liou HH
    Pharmacotherapy; 2008 Jan; 28(1):35-41. PubMed ID: 18154472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.
    Kidd RS; Straughn AB; Meyer MC; Blaisdell J; Goldstein JA; Dalton JT
    Pharmacogenetics; 1999 Feb; 9(1):71-80. PubMed ID: 10208645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza immunization does not predominantly alter levels of phenytoin, and cytochrome P-450 enzymes in epileptic patients receiving phenytoin monotherapy.
    Soontornpun A; Manoyana N; Apaijai N; Pinyopornpanish K; Pinyopornpanish K; Nadsasarn A; Tanprawate S; Chattipakorn N; Chattipakorn SC
    Epilepsy Res; 2020 Nov; 167():106471. PubMed ID: 33007725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients.
    Ramasamy K; Narayan SK; Shewade DG; Chandrasekaran A
    Ther Drug Monit; 2010 Dec; 32(6):762-6. PubMed ID: 21068649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C9 Genotypes Modify Benzodiazepine-Related Fall Risk: Original Results From Three Studies With Meta-Analysis.
    Ham AC; Ziere G; Broer L; Swart KM; Enneman AW; van Dijk SC; van Wijngaarden JP; van der Zwaluw NL; Brouwer-Brolsma EM; Dhonukshe-Rutten RA; van Schoor NM; Zillikens MC; van Gelder T; de Vries OJ; Lips P; Deeg DJ; de Groot LC; Hofman A; Witkamp RF; Uitterlinden AG; Stricker BH; van der Velde N
    J Am Med Dir Assoc; 2017 Jan; 18(1):88.e1-88.e15. PubMed ID: 27889507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.